Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Transplant Clear all
Completed Phase 3 Interventional Results available

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

NCT00358501
View directory record Official record
Conditions
Severe Hepatic Veno-Occlusive Disease
Interventions
Defibrotide
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
22
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 20, 2026, 7:36 AM EDT
Completed No phase listed Observational

Medication Adherence in Children Who Had a Liver Transplant

NCT01154075
View directory record Official record
Conditions
Pediatric Recipients of a Liver Transplant
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
1 Year to 18 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 20, 2026, 7:36 AM EDT
Completed Not applicable Interventional Results available

Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation

NCT05045794
View directory record Official record
Conditions
End Stage Liver DIsease, Liver Failure
Interventions
VitaSmart™Liver Machine Perfusion System, Static cold storage
Device · Other
Lead sponsor
Bridge to Life Ltd.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
San Bernadino, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 7:36 AM EDT
Withdrawn Phase 4 Interventional

Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment

NCT00167557
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon, Ribavirin, Liver Biopsy
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 20, 2026, 7:36 AM EDT
Terminated Phase 4 Interventional Results available

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

NCT03208127
View directory record Official record
Conditions
End Stage Liver Disease, Hepatitis C
Interventions
Treatment with Direct Acting Antiviral tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 20, 2026, 7:36 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Hepatic Transplantation Registry

NCT05944042
View directory record Official record
Conditions
Identify More Accurate Predictive Models of Transplant Risk to Monitor and Evaluate New and Existing Patient Factors
Interventions
Observational Transplant Analysis
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 20, 2026, 7:36 AM EDT
Completed No phase listed Observational Results available

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

NCT01028651
View directory record Official record
Conditions
Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 20, 2026, 7:36 AM EDT
Recruiting Phase 2 Interventional

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

NCT06280950
View directory record Official record
Conditions
Liver Transplant
Interventions
Everolimus, Tacrolimus (continued reduction), Tacrolimus (maintain 50% reduction)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 7:36 AM EDT
Recruiting No phase listed Observational

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921
View directory record Official record
Conditions
Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
Interventions
Observational Protocol
Other
Lead sponsor
European Foundation for Study of Chronic Liver Failure
Other
Eligibility
18 Years to 80 Years
Enrollment
3,000 participants
Timeline
2021 – 2026
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 20, 2026, 7:36 AM EDT
Terminated Phase 1 Interventional

Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection

NCT01560468
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
ITX 5061
Drug
Lead sponsor
Schiano, Thomas D., MD
Other
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 20, 2026, 7:36 AM EDT
Completed No phase listed Observational

Alcohol Biomarkers in Post-Liver Transplant Patients

NCT01812226
View directory record Official record
Conditions
Alcohol-related Liver Disease
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 20, 2026, 7:36 AM EDT
Not listed Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation

NCT00450398
View directory record Official record
Conditions
Liver Diseases
Interventions
YSPSL, Placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 20, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation

NCT00003966
View directory record Official record
Conditions
Veno-occlusive Disease
Interventions
defibrotide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 18 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
9
States / cities
Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 20, 2026, 7:36 AM EDT
Withdrawn No phase listed Observational

Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

NCT04216303
View directory record Official record
Conditions
Diabetes, Liver Transplant; Complications, Kidney Transplant Failure
Interventions
hemoglobin A1c
Diagnostic Test
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 20, 2026, 7:36 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis

NCT05006430
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Fecal Microbiota Transplantation, Placebo
Biological · Other
Lead sponsor
Prasun Kumar Jalal
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 20, 2026, 7:36 AM EDT
Terminated No phase listed Observational

TruGraf Liver Gene Expression Serial Test

NCT06061341
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Interventions
TruGraf®
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 20, 2026, 7:36 AM EDT
Not listed Phase 2 Interventional

5-day Defibrotide Treatment for Hepatic SOS/VOD

NCT04313036
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Bone Marrow Transplant Complications
Interventions
Defibrotide
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 20, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

NCT00105235
View directory record Official record
Conditions
Liver Disease, Liver Transplantation
Interventions
Alemtuzumab, Cyclosporine, Mycophenolate mofetil, Tacrolimus, Liver transplant, Immunosuppression withdrawal
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 20, 2026, 7:36 AM EDT
Completed Not applicable Interventional Results available

A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients

NCT04587024
View directory record Official record
Conditions
Medication Adherence, Liver Transplantation, Kidney Transplantation
Interventions
mHealth intervention, standard of care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 20, 2026, 7:36 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

NCT02123576
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Pentoxyfylline, Placebo, AMO Therapy
Drug
Lead sponsor
Patrick Northup, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 20, 2026, 7:36 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

NCT01884038
View directory record Official record
Conditions
Liver Transplant
Interventions
treprostinil sodium, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 20, 2026, 7:36 AM EDT
Terminated Phase 4 Interventional Results available

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant

NCT03208244
View directory record Official record
Conditions
End Stage Heart Disease, Hepatitis C
Interventions
Clinically prescribed direct acting antiviral
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 20, 2026, 7:36 AM EDT
Not yet recruiting Phase 1 Interventional

Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

NCT06649864
View directory record Official record
Conditions
Liver Transplant; Complications, Liver Diseases
Interventions
Autologous adipose derived mesenchymal stromal cells (AMSC)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 20, 2026, 7:36 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT03394365
View directory record Official record
Conditions
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions
tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 7:36 AM EDT